Biology Reference
In-Depth Information
204. Jansson A, Arbman G, Zhang H, Sun XF. Combined deficiency of
hMLH1, hMSH2, hMSH3 and hMSH6 is an independent prog-
nostic factor in colorectal cancer. Int J Oncol 2003;
224. Li D, Liu H, Jiao L, et al. Significant effect of homologous
recombination DNA repair gene polymorphisms on pancreatic
cancer survival. Cancer Res 2006;
:41
e
9.
205. Velasco A, Hewitt SM, Albert PS, et al. Differential expression of
the mismatch repair gene hMSH2 in malignant prostate tissue is
associated with cancer recurrence. Cancer 2002;
22
:3323
e
30.
225. de las Penas R, Sanchez-Ronco M, Alberola V, et al. Poly-
morphisms in DNA repair genes modulate survival in cisplatin/
gemcitabine-treated non-small-cell
66
:690
e
9.
206. Brueckl WM, Heinze E, Milsmann C, et al. Prognostic significance
of microsatellite instability in curatively resected adenocarcinoma
of the small intestine. Cancer Lett 2004;
94
lung cancer patients. Ann
:668
e
75.
226. Korabiowska M, Tscherny M, Grohmann U, et al. Decreased
expression of Ku70/Ku80 proteins in malignant melanomas of
the oral cavity. Anticancer Res 2002;
Oncol 2006;
17
:181
e
90.
207. Taubert HW, Bartel F, Kappler M, et al. Reduced expression of
hMSH2 protein is correlated to poor survival for soft tissue
sarcoma patients. Cancer 2003;
203
:193
e
6.
227. Korabiowska M, Tscherny M, Stachura J, et al. Differential
expression of DNA nonhomologous end-joining proteins Ku70
and Ku80 in melanoma progression. Mod Pathol 2002;
22
:2273
e
8.
208. Nakata B, Wang YQ, Yashiro M, et al. Negative hMSH2 protein
expression in pancreatic carcinoma may predict a better prog-
nosis of patients. Oncol Rep 2003;
97
15
:
426
e
33.
228. Komuro Y, Watanabe T, Hosoi Y, et al. The expression pattern of Ku
correlates with tumor radiosensitivity and disease free survival in
patients with rectal carcinoma. Cancer 2002;
:997
e
1000.
209. Catto JW, Xinarianos G, Burton JL, Meuth M, Hamdy FC.
Differential expression of hMLH1 and hMSH2 is related to
bladder cancer grade, stage and prognosis but not microsatellite
instability. Int J Cancer 2003;
10
:1199
e
205.
229. Komuro Y, Watanabe T, Hosoi Y, et al. Prediction of tumor
radiosensitivity in rectal carcinoma based on p53 and Ku70
expression. J Exp Clin Cancer Res 2003;
95
:484
e
90.
210. Brueckl WM, Moesch C, Brabletz T, et al. Relationship between
microsatellite instability, response and survival in palliative
patients with colorectal cancer undergoing first-line chemo-
therapy. Anticancer Res 2003;
105
:223
e
8.
230. Kuptsova N, Kopecky KJ, Godwin J, et al. Polymorphisms in
DNA repair genes and therapeutic outcomes of AML patients
from SWOG clinical trials. Blood 2007;
22
:1773
e
7.
211. Son BH, Ahn SH, Ko CD, Ka IW, Gong GY, Kim JC. Significance
of mismatch repair protein expression in the chemotherapeutic
response of sporadic invasive ductal carcinoma of the breast.
Breast J 2004;
23
:3936
e
44.
231. Vilmar A, Santoni-Rugiu E, Sorensen JB. ERCC1, toxicity and
quality of life in advanced NSCLC patients randomized in a large
multicentre phase III trial. Eur J Cancer 2010;
109
:1554
e
62.
232. Inada M, Sato M, Morita S, et al. Associations between oxali-
platin-induced peripheral neuropathy and polymorphisms of the
ERCC1 and GSTP1 genes. Int J Clin Pharmacol Ther 2010;
46
:20
e
6.
212. Brooks KR, To K, Joshi MB, et al. Measurement of chemo-
resistance markers in patients with stage III non-small cell lung
cancer: a novel approach for patient selection. Ann Thorac Surg
2003;
10
48
:
729
e
34.
233. Gurska S, Farkasova T, Gabelova A. Radiosensitivity of cervical
cancer cell lines: the impact of polymorphisms in DNA repair
genes. Neoplasma 2007;
:187
e
93. discussion 93.
213. Pors K, Patterson LH. DNA mismatch repair deficiency, resis-
tance to cancer chemotherapy and the development of hyper-
sensitive agents. Curr Top Med Chem 2005;
76
:195
e
201.
234. Alsbeih G, El-Sebaie M, Al-Harbi N, Al-Buhairi M, Al-Hadyan K,
Al-Rajhi N. Radiosensitivity of human fibroblasts is associated
with amino acid substitution variants in susceptible genes and
correlates with the number of risk alleles. Int J Radiat Oncol Biol
Phys 2007;
54
:1133
e
49.
214. Maxwell JA, Johnson SP, McLendon RE, et al. Mismatch repair
deficiency does not mediate clinical resistance to temozolomide
in malignant glioma. Clin Cancer Res 2008;
5
:4859
e
68.
215. Scully R, Livingston DM. In search of the tumour-suppressor
functions of BRCA1 and BRCA2. Nature 2000;
14
:229
e
35.
235. Araujo FD, Pierce AJ, Stark JM, Jasin M. Variant XRCC3 impli-
cated in cancer is functional in homology-directed repair of
double-strand breaks. Oncogene 2002;
68
:429
e
32.
216. Lord CJ, Ashworth A. Targeted therapy for cancer using PARP
inhibitors. Current Opin Pharmacol 2008;
408
:363
e
9.
217. Kennedy RD, Quinn JE, Mullan PB, Johnston PG, Harkin DP. The
role of BRCA1 in the cellular response to chemotherapy. J Natl
Cancer Inst 2004;
8
:4176
e
80.
236. Carles J, Monzo M, Amat M, et al. Single-nucleotide poly-
morphisms in base excision repair, nucleotide excision repair, and
double strand break genes as markers for response to radio-
therapy in patients with Stage I to II head-and-neck cancer. Int J
Radiat Oncol Biol Phys 2006;
21
:1659
e
68.
218. James CR, Quinn JE, Mullan PB, Johnston PG, Harkin DP.
BRCA1, a potential predictive biomarker in the treatment of
breast cancer. Oncologist 2007;
96
:1022
e
30.
237. Ho AY, Atencio DP, Peters S, et al. Genetic predictors of adverse
radiotherapy effects: the Gene-PARE project. Int J Radiat Oncol
Biol Phys 2006;
66
:142
e
50.
219. Reding KW, Bernstein JL, Langholz BM, et al. Adjuvant systemic
therapy for breast cancer in BRCA1/BRCA2 mutation carriers in
a population-based study of risk of contralateral breast cancer.
Breast Cancer Res Treat 2010;
12
:646
e
55.
238. Stankovic T, Kidd AM, Sutcliffe A, et al. ATM mutations and
phenotypes in ataxia-telangiectasia families in the British Isles:
expression of mutant ATM and the risk of leukemia, lymphoma,
and breast cancer. Am J Hum Genet 1998;
65
:491
e
8.
220. Cass I, Baldwin RL, Varkey T, Moslehi R, Narod SA, Karlan BY.
Improved survival in women with BRCA-associated ovarian
carcinoma. Cancer 2003;
123
:334
e
45.
239. Angele S, Romestaing P, Moullan N, et al. ATM haplotypes and
cellular response to DNA damage: association with breast cancer
risk and clinical radiosensitivity. Cancer Res 2003;
62
:2187
e
95.
221. Font A, Taron M, Gago JL, et al. BRCA1 mRNA expression and
outcome to neoadjuvant cisplatin-based chemotherapy in
bladder cancer. Ann Oncol 2011;
97
:8717
e
25.
240. Damaraju S, Murray D, Dufour J, et al. Association of DNA repair
and steroid metabolism gene polymorphisms with clinical late
toxicity in patients treated with conformal radiotherapy for
prostate cancer. Clin Cancer Res 2006;
63
:139
e
44.
222. Papadaki C, Tsaroucha E, Kaklamanis L, et al. Correlation of
BRCA1, TXR1 and TSP1 mRNA expression with treatment
outcome to docetaxel-based first-line chemotherapy in patients
with advanced/metastatic non-small-cell lung cancer. Br J Cancer
2011;
22
:2545
e
54.
241. Andreassen CN, Alsner J, Overgaard J, et al. TGFB1 poly-
morphisms are associated with risk of late normal tissue
complications in the breast after radiotherapy for early breast
cancer. Radiother Oncol 2005;
12
:316
e
23.
223. Su C, Zhou S, Zhang L, et al. ERCC1, RRM1 and BRCA1 mRNA
expression levels and clinical outcome of advanced non-small cell
lung cancer. Med Oncol; 2010. May 14 [Epub ahead of print.].
104
75
:18
e
21.
